Prospective observational multi-poison center study of ziprasidone exposures

Clinical Toxicology

Volumn 45, Issue 7, 2007, Pages 782-786

  Klein Schwartz, Wendy ^a,f   Lofton, Amanda L ^b   Benson, Blaine E ^c   Spiller, Henry A ^d   Crouch, Barbara I ^e  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b Beverly Hospital   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

^d KENTUCKY REGIONAL POISON CENTER   (United States)

^e Utah Poison Control Center   (United States)

^f NONE   (United States)

Author keywords

Overdose; QTc prolongation; Toxicity; Ziprasidone

Indexed keywords

ALCOHOL; AMFEBUTAMONE; CLOMETHIAZOLE; CLONAZEPAM; COCAINE; DIAMORPHINE; DIPHENHYDRAMINE; FLUNITRAZEPAM; FLUOXETINE; FLUVOXAMINE; LORAZEPAM; METHYLPHENIDATE; OXYCODONE; PARACETAMOL; QUETIAPINE; VALPROIC ACID; ZIPRASIDONE; ZOLPIDEM;

ADULT; AGED; AGITATION; ARTICLE; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE SEVERITY; DROWSINESS; DRUG EXPOSURE; DRUG INTOXICATION; DRUG OVERDOSE; FEMALE; HUMAN; HYPERTENSION; HYPOTENSION; INCIDENCE; INGESTION; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; POISON CENTER; QT INTERVAL; QT PROLONGATION; SIDE EFFECT; TACHYCARDIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; OVERDOSE; PIPERAZINES; POISON CONTROL CENTERS; PROSPECTIVE STUDIES; SLEEP STAGES; TACHYCARDIA; THIAZOLES;

EID: 36749042607     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.1080/15563650701639006     Document Type: Article

References (14)

1. Geodon® (ziprasidone) [product information]. New York, NY: Pfizer Inc.; June 2002.
2. FDA Psychopharmacological Drugs Advisory Committee, Briefing Document for Zeldox Capsules (Ziprasidone HCL), July 19, 2000. Accessed March 1, 2006 at 〈http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3619b1a.pdf〉
3. Burton MB, Heslop K, Harrison K, Barnes M. Ziprasidone overdose [letter]. Am J Psychiatry 2000; 157(5):835.
4. House M. Overdose of ziprasidone [letter]. Am J Psychiatry 2002; 159(6):1061-1062.
5. Bryant SM, Zilberstein J, Cumpston KL, Magdziarz DD, Costerisan D. A case series of ziprasidone overdoses. Vet Hum Toxicol 2003; 45(2):81-82.
6. Gomez-Criado MS, Bernardo M, de Florez T, Gutierrez R, Gandia R, Ayani I. Ziprasidone overdose: Cases recorded in the database of Pfizer-Spain and literature review. Pharmacotherapy 2005; 25:1660-1665.
7. Jaffe R, Leavitt R, Wind T. QTc prolongation in multiple drug overdose [Letter]. J Clin Psychopharmacol 2004; 24:348-349.
8. Biswas AK, Zabrocki LA, Mayes KL, Morris-Kukoski CL. Cardiotoxicity associated with intentional ziprasidone and bupropion overdose. J Toxicol Clin Toxicol 2003; 41:101-104.
9. Prieto T, Benabarre A, Bernardo M. The highest intentional ziprasidone overdose was not fatal [Letter]. Acta Psychiatr Scand 2005; 112:79-80.
10. Arbuck DM. 12,800-mg ziprasidone overdose without significant ECG changes [Letter]. Gen Hosp Psychiatry 2005; 27:222-223.
11. Lackey G, Alsop J, Albertson T. Ziprasidone: A 12-month review of acute overdoses [abstract]. J Toxicol Clin Toxicol 2002; 40(5):686.
12. Lackey G, Alsop J, Albertson T. A one-year review of pediatric ziprasidone ingestions [abstract]. J Toxicol Clin Toxicol 2002; 40(5):624.
13. Watson WA, Litovitz TL, Rodgers GC, Klein-Schwartz W, Youniss J, Rose SR, Borys D, May ME. 2002 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2003; 21:353-421.
14. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., Saunders, 2005. Accessed January 20, 2006 at 〈http://home.mdconsult. com/das/book/view/54239711-2/1282/115.html〉